Company attributes
Other attributes
Aqualung Therapeutics is an early-stage biotech company that is developing immune-focused therapeutic antibodies for patients who are suffering from disorders that are characterized by acute and chronic lung and systemic inflammation. It is developing a novel, anti-inflammatory monoclonal antibody strategy for the treatment of serious inflammation and improvement of health.
Aqualung is harnessing and treating inflammatory diseases with a novel therapy of tomorrow and its mission is to provide an immune-focused biologic platform for inflammatory disorders.
Aqualung’s science-driven approaches led them to the identification of nicotinamide phosphoribosyltransferase (NAMPT) and other key proteins expressed in both acute and chronic inflammatory diseases. Aqualung Therapeutics is developing eNamptor™, a Next Gen platform comprised of ALT 100/200, humanized eNAMPT-neutralizing monoclonal antibodies; eN-AMPT-Plex, a plasma-based biomarker panel comprised of cytokines, including eNAMPT, which predicts ARDS mortality; and NAMPT-Gene, a genotyping as-say that identifies individuals at increased risk for ARDS death.
